BAY-Q-3939
Bronchiectasis
BayerPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
22 Active assets in the Bronchiectasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ciprofloxacin Centre Hospitalier Intercommunal Creteil | Phase 4 | BBB |
Azithromycin Assiut University | Phase 4 | BBB |
Lipitor University of Edinburgh | Phase 4 | BB |
Theophylline The First Affiliated Hospital of Guangzhou Medical University | Phase 4 | BB |
Roflumilast The University of Hong Kong | Phase 3 | BB |
View all 50 →
Same molecule, other indications
BAY-Q-3939 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →